Published in EJNMMI Res on May 20, 2013
Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study. Neuropsychopharmacology (2014) 0.82
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull (2015) 0.81
Reduced Dopamine Transporter Availability and Neurocognitive Deficits in Male Patients with Alcohol Dependence. PLoS One (2015) 0.76
Incongruent reduction of dopamine transporter availability in different subgroups of alcohol dependence. Medicine (Baltimore) (2016) 0.75
The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging (2017) 0.75
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 6.27
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature (1996) 4.52
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther (1988) 2.29
Smoking-induced ventral striatum dopamine release. Am J Psychiatry (2004) 1.92
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry (2008) 1.53
Functional brain imaging of tobacco use and dependence. J Psychiatr Res (2005) 1.52
Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology (2008) 1.49
Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse (2001) 1.48
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry (2002) 1.35
Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology (2006) 1.35
A pharmacologic strategy for the treatment of nicotine addiction. Synapse (1999) 1.27
The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse (2004) 1.26
Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med (1998) 1.22
The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse (2007) 1.15
Sex differences in striatal dopamine D2/D3 receptor availability in smokers and non-smokers. Int J Neuropsychopharmacol (2012) 1.14
Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol (2007) 1.13
Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol (1989) 1.08
Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A (1991) 1.06
The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging (2010) 1.06
Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets (2008) 1.03
PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology (1999) 1.02
Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse (2002) 1.01
High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry (2000) 1.00
Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology (2004) 1.00
Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage (2009) 1.00
Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res (2001) 0.99
Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse (1999) 0.99
Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.95
Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm (Vienna) (1997) 0.94
Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging (2011) 0.93
Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med (2007) 0.92
The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology (2003) 0.90
Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage (2003) 0.89
Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography. J Cereb Blood Flow Metab (2009) 0.89
Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochem Res (1989) 0.84
Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging (2006) 0.82
Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies. J Nucl Med Technol (2011) 0.80
The effects of nicotine and cigarette smoke on the monoamine transporters. Synapse (2011) 0.78
Striatal dopamine D2/D3 receptor availability in male smokers. Psychiatry Res (2005) 0.78
Effect of nicotine on dopamine uptake in COS cells possessing the rat dopamine transporter and in PC12 cells. Biochem Pharmacol (1995) 0.77
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry (2009) 6.71
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res (2005) 3.20
National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry (2003) 3.07
Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation (2004) 3.02
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging (2014) 2.51
Applying theory-driven approaches to understanding and modifying clinicians' behavior: what do we know? Psychiatr Serv (2007) 2.41
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry (2013) 2.30
Interventions for adolescent depression in primary care. Pediatrics (2006) 2.28
Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science (2009) 2.24
New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem (2005) 2.24
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry (2002) 2.22
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry (2009) 2.13
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol (2003) 2.02
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry (2007) 1.98
Improving recognition of adolescent depression in primary care. Arch Pediatr Adolesc Med (2006) 1.92
Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther (2006) 1.92
Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics (2007) 1.82
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry (2009) 1.82
Vascular inflammation imaging with 18F-FDG PET/CT: when to image? J Nucl Med (2009) 1.79
Comparison of public attributions, attitudes, and stigma in regard to depression among children and adults. Psychiatr Serv (2007) 1.66
The organizational social context of mental health services and clinician attitudes toward evidence-based practice: a United States national study. Implement Sci (2012) 1.65
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry (2003) 1.63
Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology (2012) 1.61
Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab (2009) 1.60
Public knowledge and assessment of child mental health problems: findings from the National Stigma Study-Children. J Am Acad Child Adolesc Psychiatry (2008) 1.53
Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord (2011) 1.53
Cardiac 82Rubidium PET/CT: initial European experience. Eur J Nucl Med Mol Imaging (2007) 1.51
[11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol (2007) 1.51
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Barriers to the identification and management of psychosocial issues in children and maternal depression. Pediatrics (2007) 1.48
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry (2007) 1.48
Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management. Pediatrics (2007) 1.48
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry (2012) 1.47
Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol (2003) 1.46
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol (2002) 1.45
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Cerebral impairment in chronic solvent-induced encephalopathy. Ann Neurol (2008) 1.45
Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. J Neurol (2002) 1.43
Public knowledge, beliefs, and treatment preferences concerning attention-deficit hyperactivity disorder. Psychiatr Serv (2007) 1.41
Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol (2005) 1.41
Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dement Geriatr Cogn Disord (2008) 1.41
Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol (2004) 1.40
Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry (2005) 1.39
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry (2003) 1.39
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
Disseminating child & adolescent mental health treatment methods: an international feasibility study. Rev Bras Psiquiatr (2006) 1.37
Training of evidence-based assessment and intervention approaches in cross-cultural contexts: challenges and solutions. Rev Bras Psiquiatr (2006) 1.36
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol (2003) 1.36
5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer (2010) 1.35
Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry (2006) 1.34
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med (2005) 1.32
Development of adaptable and flexible treatment manuals for externalizing and internalizing disorders in children and adolescents. Rev Bras Psiquiatr (2006) 1.32
Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol (2010) 1.31
Reliability of the services for children and adolescents-parent interview. J Am Acad Child Adolesc Psychiatry (2004) 1.31
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36. Mol Imaging Biol (2013) 1.25
Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One (2011) 1.24
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging (2003) 1.23
Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry (2002) 1.23
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med (2008) 1.23
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage (2009) 1.23
The Application of Behavior Change Theory to Family-Based Services: Improving Parent Empowerment in Children's Mental Health. J Child Fam Stud (2010) 1.23
Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry (2005) 1.21
Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med (2003) 1.21